Good
Mostly Aligned
Patient Risk:
Low
Summary
Most identity/mechanism and administration-location statements are consistent with the provided label excerpts (instillation into dysfunctional CVADs and minimal systemic exposure when used as directed). However, several mechanism-of-action claims (plasminogen→plasmin; plasmin breaks down fibrin) are not supported by the provided labeling excerpts, and contraindication details beyond hypersensitivity and many interaction claims cannot be validated from the excerpts.
Category Scores
Accurate Statements
Cathflo is the brand name for alteplase.
Drug identity is consistent with label excerpt: “Cathflo Activase (Alteplase)” (1, 2, and other sections).
Cathflo is used to restore blood flow in certain catheter or shunt devices when blocked by a clot or fibrin buildup.
Indication: “restoration of function to central venous access devices… as assessed by ability to withdraw blood” (INDICATIONS AND USAGE).
Cathflo delivers tissue plasminogen activator (tPA) activity.
The label identifies alteplase as “tissue plasminogen activator” in the provided active ingredient description (Drug and active ingredient(s) section).
Cathflo allows fluid or blood to move through the device again.
Indication based on “restoration of function… as assessed by the ability to withdraw blood” (INDICATIONS AND USAGE).
Cathflo is typically given into the blocked catheter lumen as an instillation.
Dosage/admin: “for instillation into the dysfunctional catheter… at a concentration of 1 mg/mL” (DOSAGE AND ADMINISTRATION).
Cathflo is not injected into the bloodstream like many other thrombolytics.
Clinical pharmacology excerpt: “circulating plasma levels of Alteplase are not expected to reach pharmacologic concentrations” when administered according to instructions (CLINICAL PHARMACOLOGY—Local vs systemic exposure).
Cathflo can increase bleeding risk if a person has certain conditions.
Bleeding precaution: “Caution should be exercised” in patients with active internal bleeding or within 48 hours of specific events; also caution with thrombocytopenia/other hemostatic defects (PRECAUTIONS—Bleeding).
Clinicians weigh risks such as active bleeding before using alteplase products.
Bleeding precaution: “Caution should be exercised with patients who have active internal bleeding…” (PRECAUTIONS—Bleeding).
Clinicians weigh risks such as recent surgery before using alteplase products.
Bleeding precaution: caution “within 48 hours: surgery…” (PRECAUTIONS—Bleeding).
Clinicians weigh risks such as bleeding disorders before using alteplase products.
Bleeding precaution: caution with “thrombocytopenia” and “other hemostatic defects…” (PRECAUTIONS—Bleeding).
Unsupported Statements
Cathflo is a thrombolytic (clot-busting) drug.
Not explicitly stated in the provided label excerpts. (The excerpts discuss thrombolytics generally and bleeding risk associated with thrombolytics, but do not explicitly label Cathflo as a thrombolytic/clot-busting within the provided text.)
Cathflo delivers tissue plasminogen activator (tPA) activity.
Only the provided 'Drug and active ingredient(s)' description mentions tPA; the FDA label excerpts included here do not independently state 'tPA activity.'
Cathflo helps convert plasminogen into plasmin.
No mechanism statement in the provided label excerpts.
Plasmin breaks down fibrin clots.
No mechanism statement in the provided label excerpts.
Cathflo equals alteplase.
While the label excerpt uses both names together (“Cathflo Activase (Alteplase)”), the claim 'equals' is not directly stated as an equivalence statement in the provided excerpts.
Cathflo is a tPA formulation of alteplase.
No explicit statement in provided label excerpts describing it as a 'tPA formulation' (tPA is referenced via 'tissue plasminogen activator' in the user-provided drug/ingredient description, not in the included FDA excerpt text).
Contradictions
Important Omissions
Contraindication: hypersensitivity to alteplase or any component is the specific contraindication stated in the provided label excerpts; the AI claims did not mention hypersensitivity.
Importance:
Moderate
Dosage specifics (e.g., 2 mg in 2 mL for ≥30 kg; weight-based internal lumen volume for <30 kg; up to two 2 mg/2 mL doses; re-administration not studied beyond two doses). The AI claims included only 'typically given as an instillation' and not dose boundaries/timing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI statements generally align with labeled precautions about bleeding and the instillation route into the dysfunctional catheter. Mechanism details were unsupported by the provided excerpts but are not direct dosing/safety instructions. Missing explicit contraindication and dosage/timing limits could reduce labeling fidelity but are not direct contradictions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several mechanism-of-action and identity phrasing claims are not supported by the provided FDA label excerpts; additionally, the AI response omitted the explicit hypersensitivity contraindication and detailed dosing limits.
Suggested Improvement
Limit statements to label-supported content: describe the indication as restoration of central venous access function/withdrawal of blood, specify instillation into the dysfunctional catheter at 1 mg/mL with labeled weight-based dosing and maximum 2 mg/2 mL per dose (and up to two doses in trials), and mention contraindication/hypersensitivity to alteplase/components.